A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine

Forensic Science International

Volumn 226, Issue 1-3, 2013, Pages

  Jornil, J ^a   Nielsen, T S ^a   Rosendal, I ^a   Ahlner, J ^b   Zackrisson, A L ^b   Boel, L W T ^a   Brock, B ^a,c  

^a AARHUS UNIVERSITY   (Denmark)

^b National Board of Forensic Medicine   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

CYP2C19; CYP2D6; Drug poisoning; Mechanistic pharmacokinetic simulation; Poor metabolizer; Venlafaxine

Indexed keywords

ALCOHOL; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DESVENLAFAXINE; DIAZEPAM; ETODOLAC; HALOPERIDOL; INSULIN DETEMIR; NITRAZEPAM; OXYCODONE; PANTOPRAZOLE; PENICILLIN V; PREGABALIN; QUETIAPINE; SIMVASTATIN; VENLAFAXINE; ZOLPIDEM;

ACCIDENTAL DEATH; ADULT; ARTICLE; AUTOPSY; CASE REPORT; CAUSE OF DEATH; DEPRESSION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG FATALITY; DRUG INTOXICATION; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PNEUMONIA; PRIORITY JOURNAL; SIMULATION;

EID: 84875632256     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2012.12.020     Document Type: Article

References (50)

1. Pilgrim J.L., Gerostamoulos D., Drummer O.H. Review: pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects. Forensic Sci. Med. Pathol. 2011, 7(2):162-184.
2. Sajantila A., Palo J.U., Ojanpera I., Davis C., Budowle B. Pharmacogenetics in medico-legal context. Forensic Sci. Int. 2010, 203(1-3):44-52.
3. Musshoff F., Stamer U.M., Madea B. Pharmacogenetics and forensic toxicology. Forensic Sci. Int. 2010, 203(1-3):53-62.
4. Muth E.A., Haskins J.T., Moyer J.A., Husbands G.E.M., Nielsen S.T., Sigg E.B. Antidepressant biochemical profile of the novel bicyclic compound WY-45,030, an ethyl cyclohexanol derivative. Biochem. Pharmacol. 1986, 35(24):4493-4497.
5. Whyte I.M., Dawson A.H., Buckley N.A. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM - Int. J. Med. 2003, 96(5):369-374.
6. Hawton K., Bergen H., Simkin S., Cooper J., Waters K., Gunnell D., Kapur N. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br. J. Psychiatry 2010, 196(5):354-358.
7. Muth E.A., Moyer J.A., Haskins J.T., Andree T.H., Husbands G.E.M. Biochemical, neurophysiological, and behavioral-effects of WY-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev. Res. 1991, 23(2):191-199.
8. Schulz M., Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 2003, 58(7):447-474.
9. Reis M., Aamo T., Ahlner J., Druid H. Reference concentrations of antidepressants. A compilation of postmortem and therapeutic levels. J. Anal. Toxicol. 2007, 31(5):254-264.
10. Launiainen T., Rasanen I., Vuori E., Ojanpera I. Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. Int. J. Legal Med. 2011, 125(3):349-358.
11. Patat A., Troy S., Burke J., Trocherie S., Danjou P., Le Coz F., Allain H., Gandon J.A. Absolute bioavailability and electroencephalographic effects of conventional and extended-release formulations of venlafaxine in healthy subjects. J. Clin. Pharmacol. 1998, 38(3):256-267.
12. Wyeth, Effexor XR Safety Information. Retrieved from FDA website April 2012,. http://www.fda.gov/Safety/MedWatch/SafetyInformation/.
13. Reis M., Lundmark J., Bjork H., Bengtsson F. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther. Drug Monit. 2002, 24(4):545-553.
14. Fogelman S.M., Schmider J., Venkatakrishnan K., von Moltke L.L., Harmatz J.S., Shader R.I., Greenblatt D.J. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 1999, 20(5):480-490.
15. McAlpine D.E., Biernacka J.M., Mrazek D.A., O'Kane D.J., Stevens S.R., Langman L.J., Courson V.L., Bhagia J., Moyer T.P. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther. Drug Monit. 2011, 33(1):14-20.
16. Lindh J.D., Annas A., Meurling L., Dahl M.L., Al-Shurbaji A. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Eur. J. Clin. Pharmacol. 2003, 59(5-6):401-406.
17. Lessard E., Yessine M.A., Hamelin B.A., O'Hara G., LeBlanc J., Turgeon J. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999, 9(4):435-443.
18. Sproule B.A., Hazra M., Pollock B.G. Desvenlafaxine succinate for major depressive disorder. Drugs Today 2008, 44(7):475-487.
19. Wyeth, Pristiq Prescribing Information 2011. Retrieved from FDA website April 2012,. http://www.fda.gov/Safety/MedWatch/SafetyInformation/.
20. Bertilsson L., Dahl M.L., Dalen P., Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 2002, 53(2):111-122.
21. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002, 3(2):229-243.
22. Desta Z., Zhao X.J., Shin J.G., Flockhart D.A. Clinical significance of the cytochrome P4502C19 genetic polymorphism. Clin. Pharmacokinet. 2002, 41(12):913-958.
23. Wedlund P.J. The CYP2C19 enzyme polymorphism. Pharmacology 2000, 61(3):174-183.
24. Shams M.E.E., Arneth B., Hiemke C., Dragicevic A., Muller M.J., Kaiser R., Lackner K., Hartter S. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J. Clin. Pharm. Ther. 2006, 31(5):493-502.
25. Wilkinson G.R., Shand D.G. Physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 1975, 18(4):377-390.
26. Howgate E.M., Yeo K.R., Proctor N.J., Tucker G.T., Rostami-Hodjegan A. Prediction of in vivo drug clearance from in vitro data. I. Impact of inter-individual variability. Xenobiotica 2006, 36(6):473-497.
27. Jamei M., Dickinson G.L., Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab. Pharmacok. 2009, 24(1):53-75.
28. Jamei M., Marciniak S., Feng K.R., Barnett A., Tucker G., Rostami-Hodjegan A. The Simcyp (R) population-based ADME simulator. Expert Opin. Drug Metab. Toxicol. 2009, 5(2):211-223.
29. Jamei M., Turner D., Yang J.S., Neuhoff S., Polak S., Rostami-Hodjegan A., Tucker G. Population-based mechanistic prediction of oral drug absorption. AAPS J. 2009, 11(2):225-237.
30. Rostami-Hodjegan A., Tucker G.T. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 2007, 6(2):140-148.
31. Zackrisson A.L., Lindblom B., Ahlner J. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin. Pharmacol. Ther. 2010, 88(3):354-359.
32. Eriksson S., Berg L.M., Wadelius M., Alderborn A. Cytochrome P450 genotyping by multiplexed real-time DNA sequencing with pyrosequencing (TM) technology. Assay Drug Dev. Technol. 2002, 1(1):49-59.
33. Sim S.C., Risinger C., Dahl M.L., Aklillu E., Christensen M., Bertilsson L., Ingelman-Sundberg M. A common novel CTP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 2006, 79(1):103-113.
34. Baselt R.C. Disposition of Toxic Drugs and Chemicals in Man 2011, Biomedical Publications, Seal Beach, CA, USA. Ninth ed.
35. Reis M., Aamo T., Spigset O., Ahlner J. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther. Drug Monit. 2009, 31(1):42-56.
36. Kingback M., Karlsson L., Zackrisson A.L., Carlsson B., Josefsson M., Bengtsson F., Ahlner J., Kugelberg F.C. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood. Forensic Sci. Int. 2012, 214(1-3):124-134.
37. Jornil J., Jensen K.G., Larsen F., Linnet K. Risk assessment of accidental nortriptyline poisoning: the importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator. Eur. J. Pharm. Sci. 2011, 44(3):265-272.
38. Hasselstroem J., Linnet K. In vitro studies on quetiapine metabolism using the substrate depletion approach with focus on drug-drug interactions. Drug Metab. Drug Interact. 2006, 21(3-4):187-211.
39. Bakken G.V., Rudberg I., Molden E., Refsum H., Hermann M. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther. Drug Monit. 2011, 33(2):222-226.
40. Castberg I., Skogvoll E., Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J. Clin. Psychiatry 2007, 68(10):1540-1545.
41. Hasselstrom J., Linnet K. Quetiapine serum concentrations in psychiatric patients - the influence of comedication. Ther. Drug Monit. 2004, 26(5):486-491.
42. Lalovic B., Phillips B., Risler L.L., Howald W., Shen D.D. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab. Dispos. 2004, 32(4):447-454.
43. Andreassen T.N., Klepstad P., Davies A., Bjordal K., Lundstrom S., Kaasa S., Dale O. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur. J. Clin. Pharmacol. 2011, 67(5):493-506.
44. Klamerus K.J., Maloney K., Rudolph R.L., Sisenwine S.F., Jusko W.J., Chiang S.T. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J. Clin. Pharmacol. 1992, 32(8):716-724.
45. Klamerus K.J., Parker V.D., Rudolph R.L., Derivan A.T., Chiang S.T. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy 1996, 16(5):915-923.
46. Veefkind A.H., Hafmans P.M.J., Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther. Drug Monit. 2000, 22(2):202-208.
47. Russel F.G.M. Transporters: Importance in Drug Absorption, Distribution, and Removal, in Enzyme- and Transporter-based Drug-drug Interactions 2010, 27-49. Springer Science+Business Media, New York. K.S. Pang, A.D. Rodrigues, R.M. Peter (Eds.).
48. Otton S.V., Ball S.E., Cheung S.W., Inaba T., Rudolph R.L., Sellers E.M. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br. J. Clin. Pharmacol. 1996, 41(2):149-156.
49. Benet L.Z. A holy grail of clinical pharmacology: prediction of drug pharmacokinetics and pharmacodynamics in the individual patient. Clin. Pharmacol. Ther. 2009, 86(2):133-134.
50. DeMaio W., Kane C.P., Nichols A.I., Jordan R. Metabolism studies of desvenlafaxine. J. Bioequiv. Availab. 2011, 3:151-160.